Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.
Also called NCT01758471
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 160 participants
- Registry
-
NCT01758471
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01758471. Randomized; no masking; primary purpose basic science. Start 2012-12 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Glipizide
- Intervention (Drug)
- Acarbose
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
Record details
- Record id
cardio:ct-nct01758471- Content hash
ff7565e27faa4899485f389e05410e4ce81a8c67127884a8c5ea9141298b2ff4